Skip to content

The Gut Metagenome Research of Schizophrenia

The Gut Metagenome Research of Schizophrenia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02708316
Enrollment
200
Registered
2016-03-15
Start date
2016-04-30
Completion date
2022-12-31
Last updated
2021-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Research already found that patients with autistic spectrum disorders lack of Prevotella intestinal type, then schizophrenia patients may also show the specific intestinal type, so investigators want to detect the gut metagenome of schizophrenia patients by high-throughput DNA sequencing to find specific intestinal type, so as to achieve the purpose of schizophrenia diagnosis. According to the detection of inflammatory factors in the blood, nerve growth factor in the cerebrospinal fluid, to find the mechanism of the gut-microbes-brain axis. Furthermore, investigators want to identify intestinal strains involved in weight gain and metabolic disorders such as blood glucose and lipids induced by antipsychotic drugs.

Detailed description

A prospective observational study will be conducted and cases will be recruited by multi-center cooperation. Investigators plan to collect 100 schizophrenic patients as case group, 100 healthy people as control group. Investigators will observe schizophrenia patients who use the single drug of risperidone in the treatment and follow up the patients on day 1, the third week, the third month, the sixth month and the first year. In addition, the other two groups of patients with schizophrenia will be included, one with olanzapine and the other with aripiprazole. There are three objectives: 1. Compare healthy population with schizophrenia patients in the difference of gut metagenome and inflammatory factors in the blood, stool samples aimed at detecting the difference of composition of intestinal microorganism; 2. Observe the change of intestinal microorganism, inflammatory factors, γ-aminobutyric acid of schizophrenic patients who received risperidone treatment according to the blood, stool samples, cerebrospinal fluid during the follow-up period. 3. Study the difference of intestinal flora composition between schizophrenia patients with metabolic disorder and schizophrenia patients without metabolic disorder after olanzapine or aripiprazole treatment and discuss the relationship between intestinal flora composition and metabolic disorder.

Interventions

GENETICsequencing faecal metagenome

sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.

Sponsors

Rehabilitation Hospital of Bao Ji City
CollaboratorUNKNOWN
Center Hospital of Xian Yang City
CollaboratorUNKNOWN
Mental Health Center of Wei Nan City
CollaboratorUNKNOWN
First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* The first episode or recurrent acute-exacerbation schizophrenia patients who correspond to the Diagnostic and Statistical Manual of Mental Disorders-Ⅵ (DSM-Ⅵ) diagnostic criteria. * Between 18 and 45 years old (including 18 and 45 years old, male or female). * Patients never accepted full range of psychotropic drugs before admission(taking psychotropic drug less than 5 days before admission) * the duration of recurrent patients is less than 5 years * the period of taking psychiatric drug before admission is no more than 2 weeks. * didn't use of antibiotics within consecutive 3 days in recent 3 months. * meet the indications of a single antipsychotic risperidone treatment. * All the patients must have a good family support and comply with the requirements and signed informed consent * The PANSS score is greater than 60 or equal to 60. * BMI is greater than or equal 17.5 and less than or equal to 30.

Exclusion criteria

* Patients have severe unstable cardiovascular disease, liver disease, kidney disease, blood disease and endocrine disease or history. * Patients have the history of systematic disease or history of malignant tumor or relevant complications. * Patients have the activity of gastrointestinal diseases. * Patients have organic brain disease or complications and mental retardation. * According to the DSM-Ⅵ diagnostic criteria , patients have drug abuse or drug dependence and incomplete remission. * glutamic-oxalacetic transaminase (AST) or glutamic-pyruvic transaminase (ALT) is 2 times higher than the normal limit. * Renal dysfunction, creatinine is higher than the upper limit of normal value. * The women in pregnancy or lactation now, and may be in pregnant during the study period. * Patients are allergic to risperidone.

Design outcomes

Primary

MeasureTime frameDescription
species-level molecular operational taxonomic unitsat the beginningThe composition of the gut microbe was evaluated by sequencing faecal metagenome. The specific measures representing the above characteristics of gut microbe contain species-level molecular operational taxonomic units.

Secondary

MeasureTime frameDescription
concentration of γ-aminobutyric acidat the beginningγ-aminobutyric acid was measured by high efficiency liquid chromatography in cerebrospinal fluid, the measure unit is mg/kg
gene profilesat the beginningThe composition of the gut microbe was evaluated by sequencing faecal metagenome. The specific measures representing the above characteristics of gut microbe contain gene profiles.
concentration of inflammatory factorsat the beginningconcentration of inflammatory factors including interleukin-1(IL-1),interleukin-10(IL-10),interleukin-2 (IL-2),interleukin-6 (IL-6),tumor necrosis factor (TNF), the measure unit is U/mL
Encyclopedia of Genes and Genomes (KEGG) orthologat the beginningThe composition of the gut microbe was evaluated by sequencing faecal metagenome. The specific measures representing the above characteristics of gut microbe contain Encyclopedia of Genes and Genomes (KEGG) ortholog.
module and pathway profiles of faecal microbiotaat the beginningThe composition of the gut microbe was evaluated by sequencing faecal metagenome. The specific measures representing the above characteristics of gut microbe contain module and pathway profiles of faecal microbiota.
metagenomic linkage groupsat the beginningThe composition of the gut microbe was evaluated by sequencing faecal metagenome. The specific measures representing the above characteristics of gut microbe contain metagenomic linkage groups.

Countries

China

Contacts

Primary ContactXiancang Ma, MD,PHD
maxiancang@163.com008613002951782

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026